Skip to main content

Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Agency: National Institutes of Health

Assistance Listings
  • 93.394 -- Cancer Detection and Diagnosis Research
  • 93.395 -- Cancer Treatment Research

Forecasted opportunityLast Updated: May 13, 2026

Important dates

  • Forecasted post date: August 29, 2025
  • Forecasted application due date: October 30, 2025
  • Forecasted award date: July 1, 2026
  • Forecasted project start date: July 1, 2026
  • Fiscal Year: 2026

Award details

  • Expected project funding: Not specified
  • Expected awards: Not specified

Award min.

Not specified

Award max.

Not specified

  • Funding opportunity number:FOR-CA-25-086
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Grant
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: June 16, 2025
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.


Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the R44 activity code. The NOFO is expected to be published in Summer 2025 with an anticipated application due date in Fall 2025.

Eligibility

Nonprofit

  • Nonprofits non-higher education with 501(c)(3)
  • Other Native American tribal organizations

Government

  • Public and Indian housing authorities
  • State governments
  • County governments
  • Federally recognized Native American tribal governments

Business

  • Small businesses
  • For-profit organizations other than small businesses

Education

  • Public and state institutions of higher education
  • Independent school districts
  • Private institutions of higher education

Additional information on eligibility

Not specified

Documents

No documents are currently available.

Agency contact information

Email: francakohjc@mail.nih.gov

francakohjc@mail.nih.gov

Jonathan Franca-Koh, Ph.D., M.B.A. National Cancer Institute (NCI) 240-618-0984

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov